UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

Journal of the American College of Cardiology, 2013-12, Vol.62 (23), p.2178-2184

2013

Volltextzugriff (PDF)

Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding

Journal of lipid research, 2018-07, Vol.59 (7), p.1266-1275

2018

Volltextzugriff (PDF)

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2010-03, Vol.375 (9719), p.998-1006

2010

Volltextzugriff (PDF)

Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy

Clinics in laboratory medicine, 2006-12, Vol.26 (4), p.847-870

2006

Volltextzugriff (PDF)

Oreo Cookie Treatment Lowers LDL Cholesterol More Than High-Intensity Statin therapy in a Lean Mass Hyper-Responder on a Ketogenic Diet: A Curious Crossover Experiment

Metabolites, 2024-01, Vol.14 (1), p.73

2024

Volltextzugriff (PDF)

LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management

Journal of clinical lipidology, 2007-12, Vol.1 (6), p.583-592

2007

Volltextzugriff (PDF)

Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level

The American journal of cardiology, 2017-02, Vol.119 (3), p.404-409

2017

Volltextzugriff (PDF)

Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data

The Lancet. Digital health, 2019-12, Vol.1 (8), p.e393-e402

2019

Volltextzugriff (PDF)

Low-density lipoprotein particle number and risk for cardiovascular disease

Current atherosclerosis reports, 2004-09, Vol.6 (5), p.381-387

2004

Volltextzugriff (PDF)

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk: A Randomized, Double-Blind, Placebo-Controlled Trial

Journal of the American College of Cardiology, 2013-12, Vol.62 (23), p.2178-2184

2013

Volltextzugriff (PDF)

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Journal of clinical lipidology, 2011-05, Vol.5 (3), p.133-140

2011

Volltextzugriff (PDF)

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Journal of clinical lipidology, 2011-06, Vol.5 (3 Suppl), p.S1-S8

2011

Volltextzugriff (PDF)

Measurement issues related to lipoprotein heterogeneity

The American journal of cardiology, 2002-10, Vol.90 (8), p.22-29

2002

Volltextzugriff (PDF)

Heterogeneity of Low-Density Lipoprotein Particle Number in Patients With Type 2 Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl

The American journal of cardiology, 2006-12, Vol.98 (12), p.1599-1602

2006

Volltextzugriff (PDF)

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia

Journal of clinical lipidology, 2015-03, Vol.9 (2), p.201-209

2015

Volltextzugriff (PDF)

High-density lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result?

Journal of clinical lipidology, 2007-03, Vol.1 (1), p.57-64

Cromwell, William C., MD

2007

Volltextzugriff (PDF)

Clinical utility of low-density lipoprotein particles and apolipoprotein B in patients with cardiovascular risk

The Journal of family practice, 2013-07, Vol.62 (7 Suppl), p.1-8

2013

Volltextzugriff (PDF)

Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease

Current cardiology reports, 2009-11, Vol.11 (6), p.468-475

2009

Volltextzugriff (PDF)

SAFETY AND EFFICACY OF MIPOMERSEN ADMINISTERED AS ADD-ON THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND HIGH CARDIOVASCULAR RISK

Journal of the American College of Cardiology, 2011-04, Vol.57 (14), p.E504-E504

2011

Volltextzugriff (PDF)

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Journal of clinical lipidology, 2011-05, Vol.5 (3), p.133-140

2011

Volltextzugriff (PDF)

Future issues, public policy, and public awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Journal of clinical lipidology, 2011-06, Vol.5 (3), p.S46-S51

2011

Volltextzugriff (PDF)

Safety and Efficacy of Mipomersen Administered as Add-on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk

Journal of clinical lipidology, 2012-05, Vol.6 (3), p.291-292

2012

Volltextzugriff (PDF)

Clinical utility of LDL particle number to optimize management of LDL-related cardiovascular risk

The Journal of family practice, 2016-07, Vol.65 (7), p.S1

2016

Volltextzugriff (PDF)

Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors

The American journal of cardiology, 2000-11, Vol.86 (10), p.1123-1127

2000

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Englisch
(74)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy

Oreo Cookie Treatment Lowers LDL Cholesterol More Than High-Intensity Statin therapy in a Lean Mass Hyper-Responder on a Ketogenic Diet: A Curious Crossover Experiment

Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management

Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level

Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data

Low-density lipoprotein particle number and risk for cardiovascular disease

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk: A Randomized, Double-Blind, Placebo-Controlled Trial

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Measurement issues related to lipoprotein heterogeneity

Heterogeneity of Low-Density Lipoprotein Particle Number in Patients With Type 2 Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia

High-density lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result?

Clinical utility of low-density lipoprotein particles and apolipoprotein B in patients with cardiovascular risk

Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease

SAFETY AND EFFICACY OF MIPOMERSEN ADMINISTERED AS ADD-ON THERAPY IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND HIGH CARDIOVASCULAR RISK

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Future issues, public policy, and public awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Safety and Efficacy of Mipomersen Administered as Add-on Therapy in Patients with Hypercholesterolemia and High Cardiovascular Risk

Clinical utility of LDL particle number to optimize management of LDL-related cardiovascular risk

Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors

Suchergebnisse filtern